

ANNEXURE I

Krsnaa Diagnostics Limited

Scrip Code : 543328

Quarter Ending : March, 2022

i. Composition of Board of Director

Title	Name of the Director	Category	Initial Date of Appointment	Date of Appointment	Date of cessation	Tenure	No. of Directorship in listed entities including this listed entity	No of memberships in Audit/ Stakeholder Committee(s) including this listed entity	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity
Mr.	Rajendra Mutha	Executive Director, Chairperson	22-Dec-2010	26-Apr-2021		60	1	0	0
Ms.	Pallavi Bhatevara	Executive Director, MD	29-Jan-2013	26-Apr-2021		60	1	0	0
Mr.	Yash Mutha	Executive Director	31-Jan-2019	26-Apr-2021		60	1	2	0
Mr.	Prem Pradeep	Non-Executive – Nominee Director	08-Oct-2020	08-Oct-2020			1	1	0
Mr.	Chetan Desai	Non-Executive – Independent Director	25-Apr-2021	25-Apr-2021		60	2	7	4
Ms.	Chhaya Palrecha	Non-Executive – Independent Director	25-Apr-2021	25-Apr-2021		60	1	3	1
Mr.	Prakash Iyer	Non-Executive – Independent Director	25-Apr-2021	25-Apr-2021		60	1	2	1
Mr.	Rajiva Ranjan Verma	Non-Executive – Independent Director	25-Apr-2021	25-Apr-2021		60	1	1	0

ii. Composition of Committees

Audit Committee				
Sr. No.	Name of the Committee member	Category	Appointment Date	Cessation Date
1	Chetan Desai	Non-Executive - Independent Director, Chairperson	25-Apr-2021	
2	Chhaya Palrecha	Non-Executive - Independent Director, Member	25-Apr-2021	
3	Prakash Iyer	Non-Executive - Independent Director, Member	25-Apr-2021	
4	Rajiva Ranjan Verma	Non-Executive - Independent Director, Member	25-Apr-2021	
5	Yash Mutha	Executive, Member	31-Jan-2019	
6	Prem Pradeep	Non-Executive - Nominee Director, Member	25-Apr-2021	

Stakeholders Relationship Committee

Sr. No.	Name of the Director	Category	Appointment Date	Cessation Date
1	Prakash Iyer	Non-Executive - Independent Director,Chairperson	25-Apr-2021	
2	Chetan Desai	Non-Executive - Independent Director, Member	25-Apr-2021	31-Jan-2022
3	Yash Mutha	Executive, Member	25-Apr-2021	
4	Chhaya Palrecha	Non-Executive - Independent Director, Member	31-Jan-2022	

Risk Management Committee

Sr. No.	Name of the Director	Category	Appointment Date	Cessation Date
1	Rajiva Ranjan Verma	Non-Executive - Independent Director,Chairperson	25-Apr-2021	
2	Prakash Iyer	Non-Executive - Independent Director, Member	25-Apr-2021	
3	Yash Mutha	Executive, Member	25-Apr-2021	

Nomination and Remuneration Committee

Sr. No.	Name of the Director	Category	Appointment Date	Cessation Date
1	Prakash Iyer	Non-Executive - Independent Director,Chairperson	25-Apr-2021	
2	Chhaya Palrecha	Non-Executive - Independent Director, Member	25-Apr-2021	
3	Prem Pradeep	Non-Executive - Nominee Director,Member	25-Apr-2021	
4	Chetan Desai	Non-Executive - Independent Director, Member	31-Jan-2022	

Meeting of Board of Directors				
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Whether requirement of Quorum met	Number of Directors present	Number of Independent Directors present
11-Oct-2021	31-Jan-2022	Yes	8	4
Maximum gap between any two consecutive (in number of days)		111		

Meeting of Committees					
Name of the Committee	Date(s) of meeting during of the committee in the previous quarter	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (Yes/No)	Number of Directors present	Number of independent directors present
Audit Committee	11-Oct-2021		Yes	6	4
Audit Committee		31-Jan-2022	Yes	6	4
Maximum gap between any two consecutive (in number of days) [Only for Audit Committee]		111			

Related Party Transactions		
Subject	Compliance status (Yes/No/NA)	Remark
Whether prior approval of audit committee obtained	Yes	
Whether shareholder approval obtained for material RPT	Not Applicable	
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes	

Sr. No.	Particulars	Yes/No
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee b. Nomination & remuneration committee c. Stakeholders relationship committee d. Risk management committee (applicable to the top 100 listed entities)	
3	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	
4	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	
5	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	
6	comments/observations/advice of Board of Directors may be mentioned here:	

I. Disclosure on website in terms of Listing Regulations			
Item	Compliance status (Yes/No/NA)	Company Remark	Website
As per regulation 46(2) of the LODR:			
Details of business	Yes		https://krsnaadiagnostics.com
Terms and conditions of appointment of independent directors	Yes		https://krsnaadiagnostics.com
Composition of various committees of board of directors	Yes		https://krsnaadiagnostics.com
Code of conduct of board of directors and senior management personnel	Yes		https://krsnaadiagnostics.com
Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		https://krsnaadiagnostics.com
Criteria of making payments to non-executive directors	Yes		https://krsnaadiagnostics.com
Policy on dealing with related party transactions	Yes		https://krsnaadiagnostics.com
Policy for determining 'material' subsidiaries	Yes		https://krsnaadiagnostics.com
Details of familiarization programs imparted to independent directors	Yes		https://krsnaadiagnostics.com
Email address for grievance redressal and other relevant details entity who are responsible for assisting and handling investor grievances	Yes		https://krsnaadiagnostics.com
Contact information of the designated officials of the listed entity who are responsible	Yes		https://krsnaadiagnostics.com
Financial results	Yes		https://krsnaadiagnostics.com
Shareholding pattern	Yes		https://krsnaadiagnostics.com

Details of agreements entered into with the media companies and/or their associates	Not Applicable		
Schedule of analyst or institutional investor meet and presentations made by the listed entity to analysts or institutional investors simultaneously with submission to stock	Yes		https://krsnaadiagnostics.com
New name and the old name of the listed entity	Yes		https://krsnaadiagnostics.com
Advertisements as per regulation 47 (1)	Yes		https://krsnaadiagnostics.com
Credit rating or revision in credit rating obtained by the entity for all its outstanding	Yes		https://krsnaadiagnostics.com
Separate audited financial statements of each subsidiary of the listed entity in respect of	Not Applicable		
As per other regulations of the LODR:			
Whether company has provided information under separate section on its website as per Regulation 46(2)	Yes		https://krsnaadiagnostics.com
Materiality Policy as per Regulation 30	Yes		https://krsnaadiagnostics.com
Dividend Distribution policy as per Regulation 43A (as applicable)	Yes		https://krsnaadiagnostics.com
It is certified that these contents on the website of the listed entity are correct.	Yes		https://krsnaadiagnostics.com
II Annual Affirmations			
Particulars	Regulation Number	Compliance status (Yes/No/NA)	Company Remark
<i>Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'</i>	16(1)(b) & 25(6)	Yes	
<i>Board composition</i>	17(1), 17(1A) & 17(1B)	Yes	
<i>Meeting of Board of directors</i>	17(2)	Yes	
<i>Quorum of Board meeting</i>	17(2A)	Yes	
<i>Review of Compliance Reports</i>	17(3)	Yes	
<i>Plans for orderly succession for appointments</i>	17(4)	Yes	
<i>Code of Conduct</i>	17(5)	Yes	
<i>Fees/compensation</i>	17(6)	Yes	
<i>Minimum Information</i>	17(7)	Yes	
<i>Compliance Certificate</i>	17(8)	Yes	
<i>Risk Assessment & Management</i>	17(9)	Yes	
<i>Performance Evaluation of Independent Directors</i>	17(10)	Yes	
<i>Recommendation of Board</i>	17(11)	Yes	
<i>Maximum number of directorship</i>	17A	Yes	
<i>Composition of Audit Committee</i>	18(1)	Yes	

<i>Meeting of Audit Committee</i>	18(2)	Yes	
<i>Composition of nomination & remuneration committee</i>	19(1) & (2)	Yes	
<i>Quorum of Nomination and Remuneration Committee meeting</i>	19(2A)	Yes	
<i>Meeting of nomination & remuneration committee</i>	19(3A)	Yes	
<i>Composition of Stakeholder Relationship Committee</i>	20(1), 20(2) and 20(2A)	Yes	
<i>Meeting of stakeholder relationship committee</i>	20(3A)	Yes	
<i>Composition and role of risk management committee</i>	21(1),(2),(3),(4)	Yes	
<i>Meeting of Risk Management Committee</i>	22	Yes	
<i>Vigil Mechanism</i>	22	Yes	
<i>Policy for related party Transaction</i>	23(1),(1A),(5),(6),(7) & (8)	Yes	
<i>Prior or Omnibus approval of Audit Committee for all related party transactions</i>	23(2), (3)	Yes	
<i>Approval for material related party transactions</i>	23(4)	Not Applicable	
<i>Disclosure of related party transactions on consolidated basis</i>	23(9)	Yes	
<i>Composition of Board of Directors of unlisted material Subsidiary</i>	24(1)	Not Applicable	
<i>Other Corporate Governance requirements with respect to subsidiary of listed entity</i>	24(2),(3),(4),(5) & (6)	Yes	
<i>Annual Secretarial Compliance Report</i>	24(A)	Not Applicable	
<i>Alternate Director to Independent Director</i>	25(1)	Not Applicable	
<i>Maximum Tenure</i>	25(2)	Yes	
<i>Meeting of independent directors</i>	25(3) & (4)	Yes	
<i>Familiarization of independent directors</i>	25(7)	Yes	
<i>Declaration from Independent Director</i>	25(8) & (9)	Yes	
<i>D & O Insurance for Independent Directors</i>	25(10)	Yes	
<i>Memberships in Committees</i>	26(1)	Yes	

<i>Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel</i>	26(3)	Yes	
<i>Disclosure of Shareholding by Non- Executive Directors</i>	26(4)	Not Applicable	
<i>Policy with respect to Obligations of directors and senior management</i>	26(2) & 26(5)	Yes	